Kenai Therapeutics Appoints Mark Gergen to Board of Directors Portfolio News / By Libby Nunan Kenai Therapeutics Appoints Mark Gergen to Board of Directors Read More »
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 Portfolio News / By Libby Nunan InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 Read More »
Synthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive Officer Portfolio News / By Libby Nunan Synthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive Officer Read More »
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia Portfolio News / By Libby Nunan Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia Read More »
Atavistik Bio Appoints Habib Dable to its Board of Directors Portfolio News / By Libby Nunan Atavistik Bio Appoints Habib Dable to its Board of Directors Read More »
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer Portfolio News / By Libby Nunan Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer Read More »
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress Portfolio News / By Libby Nunan Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress Read More »
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Read More »
Remix Therapeutics™ to Present at AACR Drug Discovery and Development Conference Portfolio News / By Libby Nunan Remix Therapeutics™ to Present at AACR Drug Discovery and Development Conference Read More »
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer Read More »
